<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYCLOPHOSPHAMIDE- cyclophosphamide injection, powder, for solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively.  See full prescribing information for CYCLOPHOSPHAMIDE.<br><br>CYCLOPHOSPHAMIDE for injection, for intravenous use<br>Initial U.S. Approval: 1959</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Cyclophosphamide is an alkylating drug indicated for treatment of: </p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Malignant Diseases</span>: <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span>: Hodgkin’s disease, <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span>, mixed-cell type <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, histiocytic <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, Burkitt’s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>; <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, adenocarcinoma of ovary, retinoblastoma, breast carcinoma (<a href="#i4i_section_id_ddb2b62d-4fa0-4348-8eda-4c2573cda0f4">1.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">Minimal Change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Pediatric Patients</span>: <br>biopsy proven minimal change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy (<a href="#i4i_section_id_25eee60c-7f16-4f00-b5d0-ba941456b9f1">1.2</a>)<br><span class="Underline">Limitations of Use:</span><br>The safety and effectiveness for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in adults of other <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> has not been established.</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Malignant Diseases: Adult and Pediatric Patients</span>(<a href="#i4i_section_id_68989a3c-484b-4159-af99-04a68afe6dcc">2.1</a>) </p>
<dl>
<dt>•</dt>
<dd>Intravenous: Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days.  Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly.</dd>
<dt>•</dt>
<dd>Oral: Usually 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing.</dd>
</dl>
<p class="Highlighta"><span class="Bold">Minimal Change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Pediatric Patients</span> (<a href="#i4i_section_id_dce25f23-ba6d-49bf-80f1-8df874dfc40b">2.2</a>) </p>
<dl>
<dt>•</dt>
<dd>Recommended oral dose: 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg).  Treatment beyond 90 days increases the probability of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> in males.</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Injection, sterile  white  powder: 500 mg, 1 g, and 2 g (<a href="#i4i_dosage_form_strength_id_d9026d35-0f1c-403a-a4b3-4942b05c4112">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cyclophosphamide (<a href="#i4i_contraindications_id_72bb7b21-adf6-4916-9cef-9f1da7e22eef">4</a>)</dd>
<dt>•</dt>
<dd>Urinary outflow obstruction (<a href="#i4i_contraindications_id_72bb7b21-adf6-4916-9cef-9f1da7e22eef">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone Marrow Failure</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> – Severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Close hematological monitoring is required. (<a href="#i4i_section_id_dc14f09d-e0a7-495f-9d88-555a1c217b2c">5.1</a>) </dd>
<dt>•</dt>
<dd>Urinary Tract and Renal Toxicity – <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelitis</span>, <span class="product-label-link" type="condition" conceptid="4009173" conceptname="Ureteritis">ureteritis</span>, and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> can occur.  Exclude or correct any <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstructions</span> prior to treatment. (<a href="#i4i_section_id_02c0b193-f1ae-4cf8-8b32-65e4508aa38f">5.2</a>)</dd>
<dt>•</dt>
<dd>Cardiotoxicity – <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myopericarditis</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, which may be fatal, have been reported.  Monitor patients, especially those with risk factors for cardiotoxicity or pre-existing cardiac disease. (<a href="#i4i_section_id_60b45438-d446-4a76-a3ff-50ad1df7fac0">5.3</a>)</dd>
<dt>•</dt>
<dd>Pulmonary Toxicity – <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> and pulmonary veno-occlusive disease leading to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> may occur.  Monitor patients for signs and symptoms of pulmonary toxicity.  (<a href="#i4i_section_id_f850d773-5c32-45c5-aa20-9c1234204e30">5.4</a>)</dd>
<dt>•</dt>
<dd>Secondary malignancies (<a href="#i4i_section_id_b1ab8efc-3742-4f9c-a1da-b9ecfd4a7ea4">5.5</a>)</dd>
<dt>•</dt>
<dd>Veno-occlusive Liver Disease - Fatal outcome can occur. (<a href="#i4i_section_id_3f73ce87-2484-4bd9-85e5-5f2134905a22">5.6</a>)</dd>
<dt>•</dt>
<dd>Embryo-Fetal Toxicity - Can cause fetal harm. Advise female patients of reproductive potential to avoid pregnancy. (<a href="#i4i_section_id_35c5cbc1-8344-487c-9afe-73b60acc3768">5.7</a>, <a href="#i4i_pregnancy_id_b46e5131-7675-4693-82f6-efbf846ab698">8.1</a>,<a href="#i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56"> 8.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions reported most often include <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#i4i_section_id_c8490150-a628-4d2f-a836-a0d8f63eb77d">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or <span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing Mothers: Discontinue drug or nursing. (<a href="#i4i_nursing_mothers_id_90175494-41d2-4779-8a4b-ce4fe5b67dd6">8.3</a>)</dd>
<dt>•</dt>
<dd>Females and males of reproductive potential: Counsel patients on pregnancy prevention and planning. (<a href="#i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56">8.6</a>)</dd>
<dt>•</dt>
<dd>Renal Patients: Monitor for toxicity in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_54ecdcb7-e96f-4397-b78b-1e593a224cfd">8.7</a>, <a href="#i4i_pharmacokinetics_id_59b72874-5ff7-443a-99f0-ccdf16c24660">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Malignant Diseases</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Minimal Change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Pediatric Patients:</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing of Malignant Diseases</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing for Minimal Change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Preparation, Handling and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone Marrow Failure</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Urinary Tract and Renal Toxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Cardiotoxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Pulmonary Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Secondary Malignancies</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Veno-occlusive Liver Disease</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Impairment of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Common Adverse Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_e0baf544-ae35-4ecb-8ea8-e8ba67f1d8f7"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ddb2b62d-4fa0-4348-8eda-4c2573cda0f4"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Malignant Diseases</h2>
<p class="First">Cyclophosphamide is indicated for the treatment of:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span> (nodular or diffuse), mixed-cell type <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, histiocytic <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, Burkitt’s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span>: <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic lymphocytic leukemia</span>, <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic granulocytic leukemia</span> (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, acute lymphoblastic (stem-cell) <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (cyclophosphamide given during remission is effective in prolonging its duration)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span> (advanced disease)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span> (disseminated disease)</dd>
<dt>•</dt>
<dd>adenocarcinoma of the ovary</dd>
<dt>•</dt>
<dd>retinoblastoma</dd>
<dt>•</dt>
<dd>carcinoma of the breast</dd>
</dl>
<p>Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25eee60c-7f16-4f00-b5d0-ba941456b9f1"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Minimal Change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Pediatric Patients:</h2>
<p class="First">Cyclophosphamide is indicated for the treatment of biopsy proven minimal change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy.</p>
<p><span class="Underline">Limitations of Use:</span><br>The safety and effectiveness for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in adults or other <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_0ca0bfa4-66fd-45f6-8b73-47d502bde2e3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">During or immediately after the administration, adequate amounts of fluid should be ingested or infused to force <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide should be administered in the morning.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68989a3c-484b-4159-af99-04a68afe6dcc"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing of Malignant Diseases</h2>
<p class="First"><span class="Italics">Adults and Pediatric Patients</span></p>
<p><span class="Underline">Intravenous</span><br>When used as the only oncolytic drug therapy, the initial course of cyclophosphamide for patients with no hematologic deficiency usually consists of 40 mg per kg to 50 mg per kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly.</p>
<p><span class="Underline">Oral</span><br>Oral cyclophosphamide dosing is usually in the range of 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing.</p>
<p>Many other regimens of intravenous and oral cyclophosphamide have been reported. Dosages must be adjusted in accord with evidence of antitumor activity and/or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. The total leukocyte count is a good, objective guide for regulating dosage. </p>
<p>When cyclophosphamide is included in combined cytotoxic regimens, it may be necessary to reduce the dose of cyclophosphamide as well as that of the other drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dce25f23-ba6d-49bf-80f1-8df874dfc40b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing for Minimal Change <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Pediatric Patients</h2>
<p class="First">An oral dose of 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg) is recommended. Treatment beyond 90 days increases the probability of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> in males <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pediatric_use_id_cab84a7d-4355-409b-8959-30b9530ba1a2">8.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bbcfa14-984d-4ae8-bff1-8cf5878f6c71"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Preparation, Handling and Administration</h2>
<p class="First">Handle and dispose of cyclophosphamide in a manner consistent with other cytotoxic drugs.<a href="#i4i_references_id_a6d597ba-6c94-4cf7-aad9-55ca497b4133">1</a>  Caution should be exercised when handling and preparing Cyclophosphamide for Injection, USP. To minimize the risk of dermal exposure, always wear gloves when handling vials containing Cyclophosphamide for Injection, USP.</p>
<p><span class="Bold">Cyclophosphamide for Injection, USP</span></p>
<p><span class="Italics">Intravenous Administration</span></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use cyclophosphamide vials if there are signs of melting. Melted cyclophosphamide is a clear or yellowish viscous liquid usually found as a connected phase or in droplets in the affected vials.  </p>
<p>Cyclophosphamide does not contain any antimicrobial preservative and thus care must be taken to assure the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of prepared solutions. Use aseptic technique.</p>
<p><span class="Italics">For Direct Intravenous Injection</span></p>
<p>Reconstitute Cyclophosphamide with 0.9% Sodium Chloride Injection, USP only, using the volumes listed below in <a href="#_RefIDAB008B0953DE424E9C58E52C8FBC06E6">Table 1</a>. Gently swirl the vial to dissolve the drug completely.  Do not use Sterile Water for Injection, USP because it results in a hypotonic solution and should not be injected directly.</p>
<a name="_RefIDAB008B0953DE424E9C58E52C8FBC06E6"></a><table width="100%">
<caption><span>Table 1: Reconstitution for Direct Intravenous Injection </span></caption>
<col width="15%">
<col width="29%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First">Strength</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">Volume of <br>0.9% Sodium Chloride</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Cyclophosphamide Concentration</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">500 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25 mL</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="3"><p class="First">20 mg per mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1 g</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">2 g</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100 mL</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">For Intravenous Infusion</span></p>
<p>Reconstitution of Cyclophosphamide:<br>Reconstitute Cyclophosphamide using 0.9% Sodium Chloride Injection, USP or Sterile Water for Injection, USP with the volume of diluent listed below in <a href="#_RefID8444747144AF4EAA8E9D5405040FDA50">Table 2</a>. Add the diluent to the vial and gently swirl to dissolve the drug completely.</p>
<a name="_RefID8444747144AF4EAA8E9D5405040FDA50"></a><table width="100%">
<caption><span>Table 2: Reconstitution in preparation for Intravenous Infusion </span></caption>
<col width="13%">
<col width="15%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First">Strength</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">Volume of Diluent</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Cyclophosphamide</p>
<p>Concentration</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">500 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25 mL</p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1 g</p></td>
<td class="Botrule Lrule" align="center"><p class="First">50 mL</p></td>
<td class="Lrule Rrule" align="center"><p class="First">20 mg per mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">2 g</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100 mL</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
<p>Dilution of Reconstituted Cyclophosphamide:<br>Further dilute the reconstituted Cyclophosphamide solution to a minimum concentration of 2 mg per mL with any of the following diluents:</p>
<dl>
<dt>•</dt>
<dd>5% Dextrose Injection, USP </dd>
<dt>•</dt>
<dd>5% Dextrose and 0.9% Sodium Chloride Injection, USP </dd>
<dt>•</dt>
<dd>0.45% Sodium Chloride Injection, USP</dd>
</dl>
<p>To reduce the likelihood of adverse reactions that appear to be administration rate-dependent (e.g., <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, scalp burning), cyclophosphamide should be injected or infused very slowly. Duration of the infusion also should be appropriate for the volume and type of carrier fluid to be infused.</p>
<p><span class="Italics">Storage of Reconstituted and Diluted Cyclophosphamide Solution:</span></p>
<p>If not used immediately, for microbiological integrity, cyclophosphamide solutions should be stored as described in <a href="#_RefID5299F7D6D7684530A4A3F1F574F64F0B">Table 3</a>.</p>
<a name="_RefID5299F7D6D7684530A4A3F1F574F64F0B"></a><table width="100%">
<caption><span>Table 3: Storage of Cyclophosphamide Solutions </span></caption>
<col width="40%">
<col width="40%">
<col width="21%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Storage time is the total time cyclophosphamide is in solution including the time it is reconstituted in 0.9% Sterile Sodium Chloride Injection, USP or Sterile Water for Injection, USP.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First">Diluent</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">Storage</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Room Temperature</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Refrigerated</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Reconstituted Solution</span> (<span class="Bold">Without Further Dilution</span>)</p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">0.9% Sodium Chloride Injection, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">up to 24 hrs</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Up to 6 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Sterile Water for Injection, USP</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">Do not store; use immediately </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Diluted Solutions</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">0.45% Sodium Chloride Injection, USP </p></td>
<td class="Botrule Lrule" align="center"><p class="First">up to 24 hrs</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">up to 6 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">5% Dextrose Injection, USP </p></td>
<td class="Botrule Lrule" align="center"><p class="First">up to 24 hrs</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">up to 36 hrs</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">5% Dextrose and 0.9% Sodium Chloride Injection, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">up to 24 hrs</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">up to 36 hrs</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Use of Reconstituted Solution for Oral Administration</span></p>
<p>Liquid preparations of cyclophosphamide for oral administration may be prepared by dissolving cyclophosphamide for injection in Aromatic Elixir, National Formulary (NF).  Such preparations should be stored under refrigeration in glass containers and used within 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_d9026d35-0f1c-403a-a4b3-4942b05c4112"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Cyclophosphamide for Injection, USP is a sterile white powder available in</p>
<dl>
<dt>•</dt>
<dd>500 mg</dd>
<dt>•</dt>
<dd>1 g</dd>
<dt>•</dt>
<dd>2 g</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_72bb7b21-adf6-4916-9cef-9f1da7e22eef"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></dd>
<dt> </dt>
<dd>Cyclophosphamide is contraindicated in patients who have a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to it, any of its metabolites, or to other components of the product. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur.</dd>
<dt>•</dt>
<dd>Urinary Outflow Obstruction</dd>
<dt> </dt>
<dd>Cyclophosphamide is contraindicated in patients with urinary outflow obstruction <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_02c0b193-f1ae-4cf8-8b32-65e4508aa38f">5.2</a>)].</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_4a965b89-3a2d-4640-95c9-bdbedd80d4a9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc14f09d-e0a7-495f-9d88-555a1c217b2c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone Marrow Failure</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Cyclophosphamide can cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">bone marrow failure</span>, and severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> which may lead to serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>. Latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be reactivated <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_id_76418835-3a7e-43e4-abbe-1bb1c5035cdc">6.2</a>)].</span></p>
<p>Antimicrobial prophylaxis may be indicated in certain cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> at the discretion of the managing physician. In case of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>, antibiotic therapy is indicated.  Antimycotics and/or antivirals may also be indicated. </p>
<p>Monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed. Cyclophosphamide should not be administered to patients with <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> ≤1,500/mm<span class="Sup">3</span> and platelets &lt; 50,000/mm<span class="Sup">3</span>. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. G-CSF may be administered to reduce the risks of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> complications associated with cyclophosphamide use. Primary and secondary prophylaxis with G-CSF should be considered in all patients considered to be at increased risk for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> complications. The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. Peripheral blood cell counts are expected to normalize after approximately 20 days. <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone marrow failure</span> has been reported. Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02c0b193-f1ae-4cf8-8b32-65e4508aa38f"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Urinary Tract and Renal Toxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelitis</span>, <span class="product-label-link" type="condition" conceptid="4009173" conceptname="Ureteritis">ureteritis</span>, and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> have been reported with cyclophosphamide.  Medical and/or surgical supportive treatment may be required to treat protracted cases of severe <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. Discontinue cyclophosphamide therapy in case of severe <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. Urotoxicity (bladder ulceration, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contracture</span> and secondary cancer) may require interruption of cyclophosphamide treatment or cystectomy. Urotoxicity can be fatal.  Urotoxicity can occur with short-term or long-term use of cyclophosphamide. </p>
<p>Before starting treatment, exclude or correct any <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstructions</span> <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_72bb7b21-adf6-4916-9cef-9f1da7e22eef">4</a>)].</span> Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of urotoxicity and/or <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Cyclophosphamide should be used with caution, if at all, in patients with active <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Aggressive hydration with forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and frequent bladder emptying can reduce the frequency and severity of bladder toxicity. Mesna has been used to prevent severe bladder toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60b45438-d446-4a76-a3ff-50ad1df7fac0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Cardiotoxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myopericarditis</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> including <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">cardiac tamponade</span>, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, which may be fatal, have been reported with cyclophosphamide therapy. </p>
<p>Supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (including <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and flutter) and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> (including severe QT prolongation associated with <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmia</span>) have been reported after treatment with regimens that included cyclophosphamide. </p>
<p>The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.</p>
<p>Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease.</p>
<p>Monitor patients with risk factors for cardiotoxicity and with pre-existing cardiac disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f850d773-5c32-45c5-aa20-9c1234204e30"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Pulmonary Toxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> have been reported during and following treatment with cyclophosphamide. Late onset <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> (greater than 6 months after start of cyclophosphamide) appears to be associated with increased mortality. <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span> may develop years after treatment with cyclophosphamide.</p>
<p>Monitor patients for signs and symptoms of pulmonary toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1ab8efc-3742-4f9c-a1da-b9ecfd4a7ea4"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Secondary Malignancies</h2>
<p class="First">Cyclophosphamide is genotoxic <span class="Italics">[see Nonclinical Toxicology (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_796e7949-9504-4208-a9c7-6c1f19c3846a">13.1</a>)]</span>. Secondary malignancies (urinary tract cancer, <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span>, <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemias</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, thyroid cancer, and <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>) have been reported in patients treated with cyclophosphamide-containing regimens<span class="Italics">.</span> The risk of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> may be reduced by prevention of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f73ce87-2484-4bd9-85e5-5f2134905a22"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Veno-occlusive Liver Disease</h2>
<p class="First">Veno-occlusive liver disease (VOD) including fatal outcome has been reported in patients receiving cyclophosphamide-containing regimens. A cytoreductive regimen in preparation for bone marrow transplantation that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified as a major risk factor. VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide. Other risk factors predisposing to the development of VOD include preexisting disturbances of hepatic function, previous radiation therapy of the abdomen, and a low performance status.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35c5cbc1-8344-487c-9afe-73b60acc3768"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Embryo-Fetal Toxicity</h2>
<p class="First">Cyclophosphamide can cause fetal harm when administered to a pregnant woman <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pregnancy_id_b46e5131-7675-4693-82f6-efbf846ab698">8.1</a>)]</span>. Exposure to cyclophosphamide during pregnancy may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>, and fetotoxic effects in the newborn. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys.  </p>
<p>Advise female patients of reproductive potential to avoid becoming pregnant and to use highly effective contraception during treatment and for up to 1 year after completion of therapy<span class="Italics"> [see Use in Specific Populations (<a href="#i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56">8.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c963e5f6-51bf-4d71-bb51-646afcae96b8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></h2>
<p class="First">Male and female reproductive function and fertility may be impaired in patients being treated with cyclophosphamide. Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> in both sexes. Development of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment. Cyclophosphamide-induced <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be irreversible in some patients. Advise patients on the potential risks for <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pediatric_use_id_cab84a7d-4355-409b-8959-30b9530ba1a2">8.4</a> and <a href="#i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56">8.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9402f73-32b7-4828-9d65-d15fa320d4e3"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Impairment of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing</h2>
<p class="First">Cyclophosphamide may interfere with normal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e6bc6e0-fbba-4f60-b985-76a5dc21059b"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> associated with increased total body water, acute <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>, and a syndrome resembling <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span> (syndrome of inappropriate secretion of antidiuretic hormone), which may be fatal, has been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_fd1f26f7-0860-49f5-b16f-5bd2a3b754db"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling.</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> [see Contraindications <span class="Italics">(<a href="#i4i_contraindications_id_72bb7b21-adf6-4916-9cef-9f1da7e22eef">4</a>)</span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone Marrow Failure</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_dc14f09d-e0a7-495f-9d88-555a1c217b2c">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Urinary Tract and Renal Toxicity [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_02c0b193-f1ae-4cf8-8b32-65e4508aa38f">5.2</a></span>)]</dd>
<dt>•</dt>
<dd>Cardiotoxicity [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_60b45438-d446-4a76-a3ff-50ad1df7fac0">5.3</a></span>)]</dd>
<dt>•</dt>
<dd>Pulmonary Toxicity [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_f850d773-5c32-45c5-aa20-9c1234204e30">5.4</a>)]</span>
</dd>
<dt>•</dt>
<dd>Secondary Malignancies [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_b1ab8efc-3742-4f9c-a1da-b9ecfd4a7ea4">5.5</a>)]</span>
</dd>
<dt>•</dt>
<dd>Veno-occlusive Liver Disease [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_3f73ce87-2484-4bd9-85e5-5f2134905a22">5.6</a>)]</span>
</dd>
<dt>•</dt>
<dd>Embryo-Fetal Toxicity [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_35c5cbc1-8344-487c-9afe-73b60acc3768">5.7</a>)]</span>
</dd>
<dt>•</dt>
<dd>Reproductive System Toxicity [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_c963e5f6-51bf-4d71-bb51-646afcae96b8">5.8</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#i4i_pediatric_use_id_cab84a7d-4355-409b-8959-30b9530ba1a2">8.4</a> and <a href="#i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56">8.6</a>)]</span>
</dd>
<dt>•</dt>
<dd>Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_b9402f73-32b7-4828-9d65-d15fa320d4e3">5.9</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_1e6bc6e0-fbba-4f60-b985-76a5dc21059b">5.10</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8490150-a628-4d2f-a836-a0d8f63eb77d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Common Adverse Reactions</h2>
<p class="First"><span class="Italics">Hematopoietic system: </span><br><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> occurs in patients treated with cyclophosphamide. The degree of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is particularly important because it correlates with a reduction in resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> without documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been reported in neutropenic patients.</p>
<p><span class="Italics">Gastrointestinal system:</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur with cyclophosphamide therapy. <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and, less frequently, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may occur. There are isolated reports of <span class="product-label-link" type="condition" conceptid="4216673" conceptname="Hemorrhagic colitis">hemorrhagic colitis</span>, oral <span class="product-label-link" type="condition" conceptid="442121" conceptname="Mucosal ulcer">mucosal ulceration</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurring during therapy. </p>
<p><span class="Italics">Skin and its structures:</span><br><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> occurs in patients treated with cyclophosphamide. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> occurs occasionally in patients receiving the drug. <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> of the skin and changes in nails can occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76418835-3a7e-43e4-abbe-1bb1c5035cdc"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified from clinical trials or post-marketing surveillance. Because they are reported from a population from unknown size, precise estimates of frequency cannot be made.</p>
<p><span class="Italics">Cardiac: </span><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> (progressing to <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">cardiac tamponade</span>), myocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (including fatal outcomes), <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, carditis, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, QT prolongation.</p>
<p><span class="Italics">Congenital, Familial and Genetic</span>: intra-uterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformation</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>, fetal toxicity (including <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>).</p>
<p><span class="Italics">Ear and Labyrinth: </span><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing impaired</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>.</p>
<p><span class="Italics">Eye:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">cecitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, parotid gland <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
<p><span class="Italics">General Disorders and Administrative Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span>, general physical deterioration, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, injection/infusion site reactions (<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">bone marrow failure</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> and <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (with <span class="product-label-link" type="condition" conceptid="313800" conceptname="Thrombotic microangiopathy">thrombotic microangiopathy</span>).</p>
<p><span class="Italics">Hepatic:</span> veno-occlusive liver disease, <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">cytolytic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>; hepatotoxicity with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, blood bilirubin increased, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, hepatic enzymes increased.</p>
<p><span class="Italics">Immune:</span> <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span> The following manifestations have been associated with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> caused by cyclophosphamide: increased risk for and severity of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonias</span> (including fatal outcomes), other bacterial, fungal, viral, protozoal and, parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; reactivation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, (including <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), <span class="Italics">Pneumocystis jiroveci</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="Italics">Strongyloides</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>. </p>
<p><span class="Italics">Investigations:</span> blood lactate dehydrogenase increased, C-reactive protein increased.</p>
<p><span class="Italics">Metabolism and Nutrition: </span><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, blood glucose increased, blood glucose decreased.</p>
<p><span class="Italics">Musculoskeletal and Connective Tissue</span>: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>.</p>
<p><span class="Italics">Neoplasms: </span><span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span>, <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>, renal cell carcinoma, renal pelvis cancer, <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, ureteric cancer, thyroid cancer.</p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> has been reported and manifested as <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span>, <span class="product-label-link" type="condition" conceptid="135526" conceptname="Spinal cord disease">myelopathy</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="44783805" conceptname="Hypogeusia">hypogeusia</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>.</p>
<p><span class="Italics">Pregnancy: </span><span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span>.</p>
<p><span class="Italics">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>.</p>
<p><span class="Italics">Renal and Urinary:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4318544" conceptname="Renal tubular disorder">renal tubular disorder</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephropathy toxic</span>, <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>, <span class="product-label-link" type="condition" conceptid="4126279" conceptname="Bladder necrosis">bladder necrosis</span>, <span class="product-label-link" type="condition" conceptid="4193386" conceptname="Hunner's ulcer">cystitis ulcerative</span>, bladder <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contracture</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, atypical urinary bladder epithelial cells.</p>
<p><span class="Italics">Reproductive System: </span><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">ovarian failure</span>, <span class="product-label-link" type="condition" conceptid="4207977" conceptname="Disorder of ovary">ovarian disorder</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>. </p>
<p><span class="Italics">Respiratory: </span>pulmonary veno-occlusive disease, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> as manifested by <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (including fatal outcomes), <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">obliterative bronchiolitis</span>, <span class="product-label-link" type="condition" conceptid="4045260" conceptname="Bronchiolitis obliterans organizing pneumonia">organizing pneumonia</span>, <span class="product-label-link" type="condition" conceptid="433233" conceptname="Mushroom workers' lung">alveolitis allergic</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, nasal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>.</p>
<p><span class="Italics">Skin and Subcutaneous Tissue: </span><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, palmar-plantar erythrodysesthesia syndrome, radiation recall <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruption</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span><span class="Bold">:</span></span> like other cytotoxic drugs, cyclophosphamide may induce tumor-lysis syndrome and <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> in patients with rapidly growing tumors.</p>
<p><span class="Italics">Vascular:</span> <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_8a542fa2-ca6b-484d-a11d-e144326d03a9"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Cyclophosphamide is a pro-drug that is activated by cytochrome P450s [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_59b72874-5ff7-443a-99f0-ccdf16c24660">12.3</a>)</span>].</p>
<p>An increase of the concentration of cytotoxic metabolites may occur with:</p>
<dl>
<dt>•</dt>
<dd>Protease inhibitors: Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites. Use of protease inhibitor-based regimens was found to be associated with a higher incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in patients receiving cyclophosphamide, doxorubicin, and etoposide (CDE) than use of a Non-Nucleoside Reverse Transcriptase Inhibitor-based regimen.</dd>
</dl>
<p>Combined or sequential use of cyclophosphamide and other agents with similar toxicities can potentiate toxicities.</p>
<dl>
<dt>•</dt>
<dd>Increased hematotoxicity and/or <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may result from a combined effect of cyclophosphamide and, for example:<dl>
<dt>•</dt>
<dd>ACE inhibitors: ACE inhibitors can cause <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</dd>
<dt>•</dt>
<dd>Natalizumab</dd>
<dt>•</dt>
<dd>Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion.</dd>
<dt>•</dt>
<dd>Thiazide diuretics</dd>
<dt>•</dt>
<dd>Zidovudine</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Increased cardiotoxicity may result from a combined effect of cyclophosphamide and, for example:<dl>
<dt>•</dt>
<dd>Anthracyclines</dd>
<dt>•</dt>
<dd>Cytarabine</dd>
<dt>•</dt>
<dd>Pentostatin</dd>
<dt>•</dt>
<dd>Radiation therapy of the cardiac region</dd>
<dt>•</dt>
<dd>Trastuzumab</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Increased pulmonary toxicity may result from a combined effect of cyclophosphamide and, for example:<dl>
<dt>•</dt>
<dd>Amiodarone</dd>
<dt>•</dt>
<dd>G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor): Reports suggest an increased risk of pulmonary toxicity in patients treated with cytotoxic chemotherapy that includes cyclophosphamide and G-CSF or GMCSF.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may result from a combined effect of cyclophosphamide and, for example:<dl>
<dt>•</dt>
<dd>Amphotericin B</dd>
<dt>•</dt>
<dd>Indomethacin: Acute <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> has been reported with concomitant use of indomethacin</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Increase in other toxicities:<dl>
<dt>•</dt>
<dd>Azathioprine: Increased risk of hepatotoxicity (<span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>)</dd>
<dt>•</dt>
<dd>Busulfan: Increased incidence of hepatic veno-occlusive disease and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> has been reported.</dd>
<dt>•</dt>
<dd>Protease inhibitors: Increased incidence of <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>Increased risk of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> may result from a combined effect of cyclophosphamide and past or concomitant radiation treatment.</dd>
</dl>
<p>Etanercept:  In patients with Wegener’s granulomatosis, the addition of etanercept to standard treatment, including cyclophosphamide, was associated with a higher incidence of non-cutaneous malignant <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.</p>
<p>Metronidazole:  Acute <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> has been reported in a patient receiving cyclophosphamide and metronidazole. Causal association is unclear.  In an animal study, the combination of cyclophosphamide with metronidazole was associated with increased cyclophosphamide toxicity.</p>
<p>Tamoxifen:  Concomitant use of tamoxifen and chemotherapy may increase the risk of thromboembolic complications.</p>
<p>Coumarins:  Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide.</p>
<p>Cyclosporine:  Lower serum concentrations of cyclosporine have been observed in patients receiving a combination of cyclophosphamide and cyclosporine than in patients receiving only cyclosporine. This interaction may result in an increased incidence of graft-versus-host disease.</p>
<p>Depolarizing muscle relaxants:  Cyclophosphamide treatment causes a marked and persistent inhibition of <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> activity. Prolonged <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine). If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, alert the anesthesiologist.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_72c77f84-4b2f-45bf-89a6-e80c51a30073"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b46e5131-7675-4693-82f6-efbf846ab698"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D</p>
<p><span class="Italics">Risk Summary</span><br>Cyclophosphamide can cause fetal harm when administered to a pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. Exposure to cyclophosphamide during pregnancy may cause <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>, and toxic effects in the newborn. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.  </p>
<p><span class="Italics">Human Data</span><br>Malformations of the skeleton, palate, limbs and eyes as well as <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> have been reported after exposure to cyclophosphamide in the first trimester. <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">Fetal growth retardation</span> and toxic effects manifesting in the newborn, including <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, severe bone <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, and <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> have been reported after exposure to cyclophosphamide.</p>
<p><span class="Italics">Animal Data</span><br>Administration of cyclophosphamide to pregnant mice, rats, rabbits and monkeys during the period of organogenesis at doses at or below the dose in patients based on body surface area resulted in various malformations, which included <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, limb and digit defects and other skeletal anomalies, <span class="product-label-link" type="condition" conceptid="134144" conceptname="Cleft palate with cleft lip">cleft lip and palate</span>, and reduced skeletal ossification.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_90175494-41d2-4779-8a4b-ce4fe5b67dd6"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Cyclophosphamide is present in breast milk. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, low hemoglobin, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> have been reported in infants breast fed by women treated with cyclophosphamide. Because of the potential for serious adverse reactions in nursing infants from cyclophosphamide, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_cab84a7d-4355-409b-8959-30b9530ba1a2"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Pre-pubescent girls treated with cyclophosphamide generally develop secondary sexual characteristics normally and have regular menses. Ovarian <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> with apparently complete loss of germ cells after prolonged cyclophosphamide treatment in late pre-pubescence has been reported. Girls treated with cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span>.</p>
<p>Pre-pubescent boys treated with cyclophosphamide develop secondary sexual characteristics normally, but may have <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> or <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> and increased gonadotropin secretion. Some degree of <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> may occur. Cyclophosphamide-induced <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_0324922b-aec5-4dc3-917c-0d2702866367"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There is insufficient data from clinical studies of cyclophosphamide available for patients 65 years of age and older to determine whether they respond differently than younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac functioning, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Females and Males of Reproductive Potential</h2>
<p class="First"><span class="Italics">Contraception</span><br>Pregnancy should be avoided during treatment with cyclophosphamide because of the risk of fetal harm <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pregnancy_id_b46e5131-7675-4693-82f6-efbf846ab698">8.1</a>)].</span></p>
<p>Female patients of reproductive potential should use highly effective contraception during and for up to 1 year after completion of treatment.</p>
<p>Male patients who are sexually active with female partners who are or may become pregnant should use a condom during and for at least 4 months after treatment. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span><br><span class="Underline">Females </span><br><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, transient or permanent, associated with decreased estrogen and increased gonadotropin secretion develops in a proportion of women treated with cyclophosphamide.  Affected patients generally resume regular menses within a few months after cessation of therapy.  The risk of <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span> with cyclophosphamide increases with age.  <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">Oligomenorrhea</span> has also been reported in association with cyclophosphamide treatment.</p>
<p>Animal data suggest an increased risk of failed pregnancy and malformations may persist after discontinuation of cyclophosphamide as long as oocytes/follicles exist that were exposed to cyclophosphamide during any of their maturation phases. The exact duration of follicular development in humans is not known, but may be longer than 12 months <span class="Italics">[see Nonclinical Toxicology (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_796e7949-9504-4208-a9c7-6c1f19c3846a">13.1</a>)]</span>.</p>
<p><span class="Underline">Males</span><br>Men treated with cyclophosphamide may develop <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> or <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> which are normally associated with increased gonadotropin but normal testosterone secretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54ecdcb7-e96f-4397-b78b-1e593a224cfd"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites. This may result in increased toxicity <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_59b72874-5ff7-443a-99f0-ccdf16c24660">12.3</a>)]</span>. Monitor patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity. </p>
<p>Cyclophosphamide and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system being used.  In patients requiring dialysis, use of a consistent interval between cyclophosphamide administration and dialysis should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c4f7cdb-7899-495b-b6e6-44006f1c83ea"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have reduced conversion of cyclophosphamide to the active 4-hydroxyl metabolite, potentially reducing efficacy<span class="Italics"> [see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_59b72874-5ff7-443a-99f0-ccdf16c24660">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_bbdbea93-b9b3-4cf8-8d2a-c07a47465de9"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific antidote for cyclophosphamide is known. </p>
<p>Overdosage should be managed with supportive measures, including appropriate treatment for any concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, or cardiac toxicity should it occur.</p>
<p>Serious consequences of overdosage include manifestations of dose dependent toxicities such as <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, urotoxicity, cardiotoxicity (including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>), veno-occlusive <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_dc14f09d-e0a7-495f-9d88-555a1c217b2c">5.1</a>, <a href="#i4i_section_id_02c0b193-f1ae-4cf8-8b32-65e4508aa38f">5.2</a>, <a href="#i4i_section_id_60b45438-d446-4a76-a3ff-50ad1df7fac0">5.3</a> and <a href="#i4i_section_id_3f73ce87-2484-4bd9-85e5-5f2134905a22">5.6</a>)]</span>.</p>
<p>Patients who received an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be closely monitored for the development of toxicities, and hematologic toxicity in particular.</p>
<p>Cyclophosphamide and its metabolites are dialyzable. Therefore, rapid hemodialysis is indicated when treating any suicidal or accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span> prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with cyclophosphamide <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b1f2084f-13c9-4716-bf71-62a5c2b2ab90"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, and has the following structural formula:</p>
<div class="Figure">
<a name="id1041"></a><img alt="Cyclophosphamide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-01.jpg">
</div>
<p>Cyclophosphamide is a white crystalline powder with the molecular formula C<span class="Sub">7</span>H<span class="Sub">15</span>Cl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">2</span>P•H<span class="Sub">2</span>O and a molecular weight of 279.1.  Cyclophosphamide is soluble in water, saline, or ethanol.</p>
<p>Cyclophosphamide for Injection, USP is a sterile white powder available as 500 mg, 1 g, and 2 g strength vials.</p>
<dl>
<dt>•</dt>
<dd>500 mg vial contains 534.5 mg cyclophosphamide monohydrate equivalent to 500 mg cyclophosphamide</dd>
<dt>•</dt>
<dd>1 g vial contains 1069.0 mg cyclophosphamide monohydrate equivalent to 1 g cyclophosphamide</dd>
<dt>•</dt>
<dd>2 g vial contains 2138.0 mg cyclophosphamide monohydrate equivalent to 2 g cyclophosphamide</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_cb9a27b2-5d04-419f-aa76-a4452a131f96"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_0d7b4526-ad9e-4fc8-8ff7-648cf4db5bb9"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action is thought to involve cross-linking of tumor cell DNA.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_2c858f9a-da09-4af1-b92b-b81b743daacf"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites by a mixed function microsomal oxidase system. These metabolites interfere with the growth of susceptible rapidly proliferating malignant cells.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_59b72874-5ff7-443a-99f0-ccdf16c24660"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following IV administration, elimination half-life (t <span class="Sub">½</span>) ranges from 3 to 12 hours with total body clearance (CL) values of 4 to 5.6 L/h. Pharmacokinetics are linear over the dose range used clinically. When cyclophosphamide was administered at 4.0 g/m<span class="Sup">2</span> over a 90 minutes infusion, saturable elimination in parallel with first-order renal elimination describe the kinetics of the drug.</p>
<p><span class="Italics">Absorption</span><br>After oral administration, peak concentrations of cyclophosphamide occurred at one hour.  Area under the curve ratio for the drug after oral and IV administration (AUC<span class="Sub">po</span> : AUC<span class="Sub">iv</span>) ranged from 0.87 to 0.96.</p>
<p><span class="Italics">Distribution</span><br>Approximately 20% of cyclophosphamide is protein bound, with no dose dependent changes.  Some metabolites are protein bound to an extent greater than 60%.  Volume of distribution approximates total body water (30 to 50 L).</p>
<p><span class="Italics">Metabolism</span><br>The liver is the major site of cyclophosphamide activation.  Approximately 75% of the administered dose of cyclophosphamide is activated by hepatic microsomal cytochrome P450s including CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18 and 2C19, with 2B6 displaying the highest 4-hydroxylase activity. Cyclophosphamide is activated to form 4-hydroxycyclophosphamide, which is in equilibrium with its ring-open tautomer aldophosphamide. 4-hydroxycyclophosphamide and aldophosphamide can undergo oxidation by aldehyde dehydrogenases to form the inactive metabolites 4-ketocyclophosphamide and carboxyphosphamide, respectively. Aldophosphamide can undergo β-elimination to form active metabolites phosphoramide mustard and acrolein. This spontaneous conversion can be catalyzed by albumin and other proteins.  Less than 5% of cyclophosphamide may be directly detoxified by side chain oxidation, leading to the formation of inactive metabolites 2-dechloroethylcyclophosphamide. At high doses, the fraction of parent compound cleared by 4-hydroxylation is reduced resulting in non-linear elimination of cyclophosphamide in patients. Cyclophosphamide appears to induce its own metabolism. Auto-induction results in an increase in the total clearance, increased formation of 4-hydroxyl metabolites and shortened t<span class="Sub">1/2 </span>values following repeated administration at 12- to 24-hour interval.  </p>
<p><span class="Italics">Elimination</span><br>Cyclophosphamide is primarily excreted as metabolites. 10 to 20% is excreted unchanged in the urine and 4% is excreted in the bile following IV administration.</p>
<p><span class="Italics">Special Populations</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br>The pharmacokinetics of cyclophosphamide were determined following one-hour intravenous infusion to renally impaired patients.  The results demonstrated that the systemic exposure to cyclophosphamide increased as the renal function decreased. Mean dose-corrected AUC increased by 38% in the moderate renal group, (Creatinine clearance (CrCl of 25 to 50 mL/min), by 64% in the severe renal group (CrCl of 10 to 24 mL/min) and by 23% in the hemodialysis group (CrCl of &lt; 10 mL/min) compared to the control group. The increase in exposure was significant in the severe group (p&gt;0.05); thus, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be closely monitored for toxicity<span class="Italics"> [see Use in Specific Populations (<a href="#i4i_section_id_54ecdcb7-e96f-4397-b78b-1e593a224cfd">8.7</a>)]</span>. </p>
<p>The dialyzability of cyclophosphamide was investigated in four patients on long-term hemodialysis. Dialysis clearance calculated by arterial-venous difference and actual drug recovery in dialysate averaged 104 mL/min, which is in the range of the metabolic clearance of 95 mL/min for the drug. A mean of 37% of the administered dose of cyclophosphamide was removed during hemodialysis. The elimination half-life (t<span class="Sub">1/2</span>) was 3.3 hours in patients during hemodialysis, a 49% reduction of the 6.5 hours to t<span class="Sub">1/2</span> reported in uremic patients. Reduction in t<span class="Sub">1/2</span>, larger dialysis clearance than metabolic clearance, high extraction efficiency, and significant drug removal during dialysis, suggest that cyclophosphamide is dialyzable.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br>Total body clearance (CL) of cyclophosphamide is decreased by 40% in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and elimination half-life (t<span class="Sub">½</span>) is prolonged by 64%.  Mean CL and t<span class="Sub">½</span> were 45 ± 8.6 L/kg and 12.5 ± 1.0 hours respectively, in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and 63 ± 7.6 L/kg and 7.6 ± 1.4 hours respectively in the control group <span class="Italics">[see Use in Specific Populations (<a href="#i4i_section_id_4c4f7cdb-7899-495b-b6e6-44006f1c83ea">8.8</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_8b26b25e-1822-4920-9f11-ff992c285002"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_796e7949-9504-4208-a9c7-6c1f19c3846a"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Cyclophosphamide administered by different routes, including intravenous, subcutaneous or intraperitoneal injection, or in drinking water, caused tumors in both mice and rats.  In addition to <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, benign and <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> were found at various tissue sites, including urinary bladder, mammary gland, lung, liver, and injection site<span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_b1ab8efc-3742-4f9c-a1da-b9ecfd4a7ea4">5.5</a>)]</span>.  </p>
<p>Cyclophosphamide was mutagenic and clastogenic in multiple <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> genetic toxicology studies.  </p>
<p>Cyclophosphamide is genotoxic in male and female germ cells. Animal data indicate that exposure of oocytes to cyclophosphamide during follicular development may result in a decreased rate of implantations and viable pregnancies, and in an increased risk of malformations. Male mice and rats treated with cyclophosphamide show alterations in male reproductive organs (e.g., decreased weights, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, changes in spermatogenesis), and decreases in reproductive potential (e.g., decreased implantations and increased post-implantation loss) and increases in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> when mated with untreated females<span class="Italics"> [see Use in Specific Populations (<a href="#i4i_section_id_6a0e4d3e-f742-460a-93e2-cf9f8233aa56">8.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_a6d597ba-6c94-4cf7-aad9-55ca497b4133"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>OSHA Hazardous Drugs. <span class="Italics">OSHA</span>. http://www.osha.gov/SLTC/hazardousdrugs/index.html.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_1e40affb-ff41-4783-8f19-1374a298d997"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Cyclophosphamide for Injection, USP is a sterile white powder containing cyclophosphamide and is supplied in vials for single dose use.</p>
<p>Cyclophosphamide for Injection, USP</p>
<dl>
<dt> </dt>
<dd> NDC 10019-955-01 500 mg vial, carton of 1<br> NDC 10019-956-01 1 g vial, carton of 1<br> NDC 10019-957-01 2 g vial, carton of 1</dd>
</dl>
<p>Store vials at or below 25°C (77°F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide. <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_7bbcfa14-984d-4ae8-bff1-8cf5878f6c71">2.3</a>)]</span>. </p>
<p>Cyclophosphamide is an antineoplastic product.  Follow special handling and disposal procedures.<a href="#i4i_references_id_a6d597ba-6c94-4cf7-aad9-55ca497b4133">1</a></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1585b5eb-553e-44f2-9296-c856ac27846c"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient of the following:</p>
<dl>
<dt>•</dt>
<dd>Inform patients of the possibility of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Explain the need for routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_dc14f09d-e0a7-495f-9d88-555a1c217b2c">5.1</a>)].</span>
</dd>
<dt>•</dt>
<dd>Advise the patient to report urinary symptoms (patients should report if their urine has turned a pink or red color) and the need for increasing fluid intake and frequent voiding <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_02c0b193-f1ae-4cf8-8b32-65e4508aa38f">5.2</a>)].</span>
</dd>
<dt>•</dt>
<dd>Advise patients to contact a healthcare professional immediately for any of the following: new onset or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the ankles/legs, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of more than 5 pounds in 24 hours, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_60b45438-d446-4a76-a3ff-50ad1df7fac0">5.3</a>)]</span>.</dd>
<dt>•</dt>
<dd>Warn patients of the possibility of developing non-infectious <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.  Advise patients to report promptly any new or worsening respiratory symptoms<span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_f850d773-5c32-45c5-aa20-9c1234204e30">5.4</a>)]</span>.</dd>
<dt>•</dt>
<dd>Advise female patients of reproductive potential to use highly effective contraception during treatment and for up to 1 year after completion of therapy.  There is a potential for harm to a fetus if a patient becomes pregnant during this period.  Patients should immediately contact their healthcare provider if they become pregnant or if pregnancy is suspected during this period <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_35c5cbc1-8344-487c-9afe-73b60acc3768">5.7</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#i4i_pregnancy_id_b46e5131-7675-4693-82f6-efbf846ab698">8.1</a>)]</span>. </dd>
<dt>•</dt>
<dd>Advise male patients who are sexually active with a female partner who is or may become pregnant to use condoms during treatment and for up to 4 months after completion of therapy.  There is a potential for harm to a fetus if a patient fathers a child during this period.  Patients should immediately contact their healthcare provider if their female partner becomes pregnant or if pregnancy is suspected during this period <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_35c5cbc1-8344-487c-9afe-73b60acc3768">5.7</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#i4i_pregnancy_id_b46e5131-7675-4693-82f6-efbf846ab698">8.1</a>)]</span>. </dd>
<dt>•</dt>
<dd>Advise nursing mothers treated with cyclophosphamide to discontinue nursing or discontinue cyclophosphamide, taking into account the importance of the drug to the mother <span class="Italics">[see Use in Specific Populations (<a href="#i4i_nursing_mothers_id_90175494-41d2-4779-8a4b-ce4fe5b67dd6">8.3</a>)].</span>
</dd>
<dt>•</dt>
<dd>Explain to patients that side effects such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span>, <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> may be associated with cyclophosphamide administration. Other undesirable effects (including, e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>) could affect the ability to drive or use machines<span class="Italics"> [see Adverse Reactions (<a href="#i4i_section_id_c8490150-a628-4d2f-a836-a0d8f63eb77d">6.1</a> and <a href="#i4i_section_id_76418835-3a7e-43e4-abbe-1bb1c5035cdc">6.2</a>)]</span>.</dd>
</dl>
<p>Manufactured by:</p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Product Made in Germany</p>
<p>Baxter is a trademark of Baxter International Inc.</p>
<p>HA-30-01-350</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_46cfb7d4-ecf2-4cdd-828e-e1de3d0e564c"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1188"></a><img alt="Cyclophosphamide Representative Container Label  NDC 10019-955-50" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-02.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p class="First">Container Label </p>
<p>LOT/EXP:</p>
<p><span class="Bold">JMXXX</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<p>NDC 10019-955-50</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">500 mg CYTOTOXIC AGENT</span></p>
<p><span class="Bold">FOR SINGLE DOSE USE</span><br><span class="Bold">STERILE, NON-PYROGENIC</span><br><span class="Bold">FOR PARENTERAL USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold"><span class="Italics">Baxter  Logo</span></span><br>Manufactured by <span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA         460-629-01</p>
<p>Each vial contains 500 mg cyclophosphamide.</p>
<p><span class="Bold">For IV Infusion Use:</span> Add 25 mL Sterile<br>Water for Injection, USP, and shake<br>vigorously to dissolve the drug.</p>
<p><span class="Bold">For Direct Injection Use:</span> Add 25 mL<br>0.9% Sodium Chloride Injection,<br>USP, and shake vigorously to dis-<br>solve the drug.</p>
<p>See insert for indications and dosage <br>schedule. <span class="Bold">Store vial at or below 25˚C</span><br><span class="Bold">(77˚F) [see USP Controlled Room</span><br><span class="Bold">Temperature].</span></p>
<p>(01)00310019955506</p>
<p><span class="Bold">USA </span>5538 152<span class="Bold">1</span> C 644</p>
<div class="Figure">
<a name="id1240"></a><img alt="Cyclophosphamide Representative Carton Label  NDC 10019-955-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-03.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
<p>NDC 10019-955-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">500 mg</span></p>
<p>1 Single Dose Vial </p>
<p>P 287 C</p>
<p>P 200 C</p>
<p>NDC 10019-955-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">500 mg       Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSION</span><br><span class="Bold">OR DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p><span class="Bold"><span class="Italics">BaxterLogo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>5738<br>109<span class="Bold">1</span><br><span class="Bold">USA</span></p>
<p>Each vial contains 500 mg cyclophosphamide.</p>
<p><span class="Bold">For IV Infusion Use: </span>Add 25 mL Sterile Water<br>for Injection, USP, and shake vigorously to<br>dissolve the drug.</p>
<p><span class="Bold">For Direct Injection Use: </span>Add 25 mL 0.9%<br>Sodium Chloride Injection, USP, and shake<br>vigorously to dissolve the drug.</p>
<p><span class="Bold">Store vial at or below 25°C</span><br><span class="Bold">(77°F) [see USP Controlled Room </span><br><span class="Bold">Temperature].</span></p>
<p><span class="Bold">DOSAGE: </span>See accompanying literature for<br>directions for use. Should not be pre-<br>scribed without thorough knowledge of<br>dose, indications and toxicity as contained<br>in accompanying literature.</p>
<p><span class="Bold">CYTOTOXIC AGENT</span></p>
<p><span class="Bold">FOR SINGLE DOSE USE</span><br><span class="Bold">STERILE, NON-PYROGENIC</span><br><span class="Bold">FOR PARENTERAL USE</span></p>
<p>460-630-01</p>
<p>C</p>
<p>661</p>
<p>NDC 10019-955-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">500 mg               Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSION</span><br><span class="Bold">OR DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>LOT /EXP:</p>
<p><span class="Bold">JMXXXA</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<p>2638B5071</p>
<p>NDC 10019-955-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">500 mg             Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSION</span><br><span class="Bold">OR DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p>N<br>3<br>10019 95501  8</p>
<div class="Figure">
<a name="id1359"></a><img alt="Cyclophosphamide Representative Container Label  NDC 10019-956-16" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-04.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p>Container Label </p>
<p>LOT/EXP:</p>
<p><span class="Bold">JMXXX</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<p>NDC 10019-956-16</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">1 gram CYTOTOXIC AGENT</span></p>
<p><span class="Bold">FOR SINGLE DOSE USE</span><br><span class="Bold">STERILE, NON-PYROGENIC</span><br><span class="Bold">FOR PARENTERAL USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold"><span class="Italics">Baxter  Logo</span></span><br>Manufactured by <span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA         460-631-01</p>
<p>Each vial contains 1 g cyclophosphamide.</p>
<p><span class="Bold">For IV Infusion Use:</span> Add 50 mL Sterile<br>Water for Injection, USP, and shake<br>vigorously to dissolve the drug.</p>
<p><span class="Bold">For Direct Injection Use:</span> Add 50 mL<br>0.9% Sodium Chloride Injection,<br>USP, and shake vigorously to dis-<br>solve the drug.</p>
<p>See insert for indications and dosage <br>schedule. <span class="Bold">Store vial at or below 25˚C</span><br><span class="Bold">(77˚F) [see USP Controlled Room</span><br><span class="Bold">Temperature].</span></p>
<p>(01)00310019956169</p>
<p><span class="Bold">USA </span>5538 153<span class="Bold">1</span> C 645</p>
<div class="Figure">
<a name="id1411"></a><img alt="Cyclophosphamide Representative Carton Label  NDC 10019-956-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-05.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
<p>NDC 10019-956-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">1 gram</span></p>
<p>1 Single Dose Vial</p>
<p>P 287 C</p>
<p>P 355 C</p>
<p>NDC 10019-956-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">1 gram    Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSION</span><br><span class="Bold">OR DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p><span class="Bold"><span class="Italics">BaxterLogo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>5738<br>110<span class="Bold">1</span><br><span class="Bold">USA</span></p>
<p>Each vial contains 1 g cyclophosphamide.</p>
<p><span class="Bold">For IV Infusion Use: </span>Add 50 mL Sterile <br>Water for Injection, USP, and shake <br>vigorously to dissolve the drug.</p>
<p><span class="Bold">For Direct Injection Use: </span>Add 50 mL <br>0.9% Sodium Chloride Injection, USP, and <br>shake vigorously to dissolve the drug.</p>
<p><span class="Bold">Store vial at or below 25°C 77°F) </span><br><span class="Bold">[see USP Controlled Room Tempera-</span><br><span class="Bold">ture].</span></p>
<p><span class="Bold">DOSAGE: </span>See accompanying literature <br>for directions for use. Should not be <br>prescribed without thorough knowledge <br>of dose, indications and toxicity as con-<br>tained in accompanying literature.</p>
<p><span class="Bold">CYTOTOXIC AGENT</span></p>
<p><span class="Bold">FOR SINGLE DOSE USE</span><br><span class="Bold">STERILE, NON-PYROGENIC</span><br><span class="Bold">FOR PARENTERAL USE</span></p>
<p>460-632-01</p>
<p>C</p>
<p>611</p>
<p>NDC 10019-956-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">1 gram      Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSIONOR </span><br><span class="Bold">DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>LOT /EXP:</p>
<p><span class="Bold">JMXXXA</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<p>2638B5072</p>
<p>NDC 10019-956-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">1 gram      Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSIONOR </span><br><span class="Bold">DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p>N<br>3<br>10019 95601  5</p>
<div class="Figure">
<a name="id1529"></a><img alt="Cyclophosphamide Representative Container Label  NDC 10019-957-11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-06.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p>Container Label </p>
<p>LOT/EXP:</p>
<p><span class="Bold">JMXXX</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<p>NDC 10019-957-11</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">2 gram CYTOTOXIC AGENT</span></p>
<p><span class="Bold">FOR SINGLE DOSE USE</span><br><span class="Bold">STERILE, NON-PYROGENIC</span><br><span class="Bold">FOR PARENTERAL USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold"><span class="Italics">Baxter  Logo</span></span><br>Manufactured by <span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA         460-633-01</p>
<p>Each vial contains 2 g cyclophosphamide.</p>
<p><span class="Bold">For IV Infusion Use:</span> Add 100 mL <br>Sterile Water for Injection, USP, and <br>shake vigorously to dissolve the drug.</p>
<p><span class="Bold">For Direct Injection Use:</span> Add 100 mL<br>0.9% Sodium Chloride Injection, USP, <br>and shake vigorously to dissolve the <br>drug.</p>
<p>See insert for indications and dosage <br>schedule. <span class="Bold">Store vial at or below 25˚C</span><br><span class="Bold">(77˚F) [see USP Controlled Room</span><br><span class="Bold">Temperature].</span></p>
<p>(01)00310019957111</p>
<p><span class="Bold">USA </span>5538 154<span class="Bold">1</span> C 647</p>
<div class="Figure">
<a name="id1581"></a><img alt="Cyclophosphamide Representative Carton Label  NDC 10019-967-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f&amp;name=image-07.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
<p>NDC 10019-957-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">2 gram</span></p>
<p>1 Single Dose Vial</p>
<p>P 287 C</p>
<p>P 258 C</p>
<p>NDC 10019-957-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">2 gram    Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSION</span><br><span class="Bold">OR DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p><span class="Bold"><span class="Italics">BaxterLogo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>5738<br>111<span class="Bold">1</span><br><span class="Bold">USA</span></p>
<p>Each vial contains 2 g cyclophosphamide.</p>
<p><span class="Bold">For IV Infusion Use: </span>Add 100 mL Sterile <br>Water for Injection, USP, and shake <br>vigorously to dissolve the drug.</p>
<p><span class="Bold">For Direct Injection Use: </span>Add 100 mL <br>0.9% Sodium Chloride Injection, USP, and <br>shake vigorously to dissolve the drug.</p>
<p><span class="Bold">Store vial at or below 25°C 77°F) [see </span><br><span class="Bold">USP Controlled Room Temperature].</span></p>
<p><span class="Bold">DOSAGE: </span>See accompanying literature <br>for directions for use. Should not be <br>prescribed without thorough knowledge <br>of dose, indications and toxicity as con-<br>tained in accompanying literature.</p>
<p><span class="Bold">CYTOTOXIC AGENT</span></p>
<p><span class="Bold">FOR SINGLE DOSE USE</span><br><span class="Bold">STERILE, NON-PYROGENIC</span><br><span class="Bold">FOR PARENTERAL USE</span></p>
<p>460-634-01</p>
<p>C</p>
<p>610</p>
<p>NDC 10019-957-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">2 gram     Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSIONOR </span><br><span class="Bold">DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>LOT /EXP:</p>
<p><span class="Bold">JMXXXA</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<p>2638B5073</p>
<p>NDC 10019-957-01</p>
<p><span class="Bold">Cyclophosphamide</span><br><span class="Bold">for Injection, USP</span></p>
<p><span class="Bold">2 gram          Rx only</span></p>
<p><span class="Bold">MUST BE DILUTED</span><br><span class="Bold">FOR IV INFUSIONOR </span><br><span class="Bold">DIRECT INJECTION USE</span></p>
<p>1 Single Dose Vial</p>
<p>N<br>3<br>10019 95701  2</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOPHOSPHAMIDE 		
					</strong><br><span class="contentTableReg">cyclophosphamide injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-955</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPHOSPHAMIDE</strong> (CYCLOPHOSPHAMIDE ANHYDROUS) </td>
<td class="formItem">CYCLOPHOSPHAMIDE ANHYDROUS</td>
<td class="formItem">500 mg  in 25 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-955-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-955-50</td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040745</td>
<td class="formItem">05/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOPHOSPHAMIDE 		
					</strong><br><span class="contentTableReg">cyclophosphamide injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-956</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPHOSPHAMIDE</strong> (CYCLOPHOSPHAMIDE ANHYDROUS) </td>
<td class="formItem">CYCLOPHOSPHAMIDE ANHYDROUS</td>
<td class="formItem">1 g  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-956-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-956-16</td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040745</td>
<td class="formItem">05/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOPHOSPHAMIDE 		
					</strong><br><span class="contentTableReg">cyclophosphamide injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-957</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPHOSPHAMIDE</strong> (CYCLOPHOSPHAMIDE ANHYDROUS) </td>
<td class="formItem">CYCLOPHOSPHAMIDE ANHYDROUS</td>
<td class="formItem">2 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-957-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-957-11</td>
<td class="formItem">100 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040745</td>
<td class="formItem">05/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Baxter Healthcare Corporation (005083209)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Oncology GmbH</td>
<td class="formItem"></td>
<td class="formItem">344276063</td>
<td class="formItem">ANALYSIS(10019-955, 10019-956, 10019-957), LABEL(10019-955, 10019-956, 10019-957), MANUFACTURE(10019-955, 10019-956, 10019-957), PACK(10019-955, 10019-956, 10019-957), STERILIZE(10019-955, 10019-956, 10019-957)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>76533b44-b0a8-44ae-80c0-ec15e4f9cc9a</div>
<div>Set id: 591d9955-3d9c-4cdc-a308-2f1288376b9f</div>
<div>Version: 5</div>
<div>Effective Time: 20141025</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
